Needham Maintains Buy on Starling Oncology, Raises Price Target to $9

Needham analyst Matthew Shea has maintained a 'Buy' rating on Starling Oncology (NASDAQ: STLN) and raised the price target from $7 to $9. This adjustment reflects a positive outlook for the company's stock performance.